In the pivotal Phase III trial of pazopanib, PFS was significantly prolonged by pazopanib treatment compared with placebo, regardless of MSKCC risk ... well tolerated in mRCC with poor prognostic ...

Total Borrowings: $293.9 million as of December 31, 2024. Monroe Capital Corp (NASDAQ:MRCC) achieved an annualized dividend yield of 11.4%, indicating strong returns for shareholders. The company ...

Monroe Capital (MRCC) came out with quarterly earnings of $0.29 per share, beating the Zacks Consensus Estimate of $0.28 per share. This compares to earnings of $0.26 per share a year ago.

MRCC delivered a total annualized dividend yield and our trading price of 11.4% using our February 28, 2025 closing share price. We are proud of our longstanding track record of delivering ...

MRCC delivered a total annualized dividend yield and our trading price of 11.4% using our February 28, 2025 closing share price. We are proud of our longstanding track record of delivering ...

Shares of MRCC stock opened at $8.81 on Monday. The company has a quick ratio of 4.37, a current ratio of 4.37 and a debt-to-equity ratio of 1.49. Monroe Capital has a twelve month low of $6.97 ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

The Lee laboratory studies the mechanisms governing homeostatic turnover and reparative programs in stem cells, with a focus on elucidating how tissue perturbations lead to lung disease. We ...

Our lab develops novel computational methods to study cellular biological systems from a global and data-driven perspective. We seek to exploit diverse, high-throughput functional and genomic data to ...